SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 217-223

  Rausch, Sarah M ^a   Gonzalez, Brian D ^a   Clark, Matthew M ^b   Patten, Christi ^b   Felten, Sara ^b   Liu, Heshan ^b   Li, Yafei ^b   Sloan, Jeff ^b   Yang, Ping ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cytokines; Genetics; LTA; Lung cancer; Pain; PTGS2; Quality of life; SNPs

Indexed keywords

DNA; LYMPHOTOXIN ALPHA BETA; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PAIN; CANCER SURVIVOR; CAUCASIAN; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 8; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; LUNG NEOPLASMS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; SEQUENCE ANALYSIS, DNA; SURVIVORS;

EID: 84862820025     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.02.017     Document Type: Article

References (78)

1. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors 2001: systematic analysis of population health data. Lancet 2006, 367(Suppl. 9524):1747-1757.
2. SEER cancer statistics review, 1975-2008 2011, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site. N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron (Eds.).
3. Sugimara H., Yang P. Long-term survivorship in lung cancer: a review. Chest 2006, 129(4):1088-1097.
4. Burkett V.S., Cleeland C.S. Symptom burden in cancer Survivorship. J Cancer Surviv 2007, 1:167-175.
5. Yang P., Cheville A.L., Wampfler J.A., Garces Y.I., Jatoi A., Clark M.M., et al. Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol 2012, 7(January (1)):64-70.
6. Balduyck B., Hendriks J., Lauwers P., Van Schil P. Quality of life after lung cancer surgery. J Thorac Oncol 2008, 3(June (6)):604-608.
7. Mantyh P.W. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006, 7(October (10)):797-809.
8. Patrick D.L., Ferketich S.L., Frame P.S., Harris J.J., Hendricks C.B., Levin B., et al. National Institutes of Health State-of-the-Science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr 2004, 32:9-16.
9. Grossman S.A., Sheidler C.R. Cancer pain. Clinical oncology 2000, 565-578. Churchill Livingstone, New York (NY). 2nd ed. M.D. Aeloff, J.O. Armitage, A.S. Lichter (Eds.).
10. Wang X.S., Cleeland C.S., Mendoza T.R., Engstrom M.C., Liu S., Xu G., et al. The effects of pain severity on health-related quality of life. Cancer 1999, 86(Suppl. 9):1848-1855.
11. de Wit R., van Dam F., Loonstra S., Zandbelt L., van Buuren A., van der Heidjen K., et al. The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 2001, 91(Suppl. 3):339-349.
12. Meuser T., Pietruck C., Radbruch L., Stute P., Lehmann K.A., Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93(Suppl. 3):247-257.
13. Cheng K.K.F., Lee D.T.F. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol 2010.
14. Strömgren A.S., Sjogren P., Goldschmidt D., Petersen M.A., Pederson L., Groenvold M. Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 2006, 31(Suppl. 3):199-206.
15. Green C.R., Hart-Johnson T., Loeffleer D.R. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer 2011, 1994-2003.
16. Davis K., Yount S., Wagner L., Cella D. Measurement and management of health-related quality f life in lung cancer. Clin Adv Hematol Oncol 2004, 2(8):533-540.
17. Burton A.W., Fanciullo G.J., Beasley R.D., Fisch M.J. Chronic pain in the cancer survivor: a new frontier. Pain Med 2007, 8(2):189-198.
18. Leung L., Cahill C.M. TNF-alpha and neuropathic pain - a review. J Neuroinflamm 2010, 7:27-38.
19. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nature 2008, 8(Suppl. 11):887-899.
20. Collado-Hidalgo A., Bower J.E., Ganz P.A., Cole S.W., Irwin M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 2006, 12(Suppl. 9):2759-2766.
21. O'Connor M.F., Irwin M.R., Seldon J., Kwan L., Ganz P.A. Pro-inflammatory cytokines and depression in a familial cancer registry. Psychooncology 2007, 16(Suppl. 5):499-501.
22. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001, 158(Suppl. 8):1252-1257.
23. Jehn C.F., Kuhnhardt D., Bartholomae A., Pfeiffer S., Schmid P., Possinger K., et al. Association of IL-6. Hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther 2010, 9(3):270-275.
24. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010, 24:968-974.
25. Panju A.H., Danesh A., Minden M.D., Kelvin D.J., Alibhai S.M. Associations between quality of life, fatigue, and cytokine levels in patients aged 50 with acute myeloid leukemia. Support Care Cancer 2009, 17(Suppl. 5):539-546.
26. Del Fabbro E., Hui D., Nooruddin Z., Dalal S., Dev R., Freer G., et al. Association between inflammatory markers, symptom burden, hypogonadism, and survival in cancer patients with cachexia. J Clin Oncol 2009, 27(Suppl. 15S):9594.
27. Brisby H., Olmarker K., Larsson K., Nutu M., Rydevik B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 2002, 11:62-66.
28. Kotani N., Kudo R., Sakurai Y., Sawamura D., Sessler D.I., Okada H., et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of posttherapeutic neuralgia. Am J Med 2004, 116:318-324.
29. Reyes-Gibby C.C., Spitz M., Wu X., Merriman K., Etzel C., Bruera E., et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-α-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 2007, 16(Suppl. 12):2745-2751.
30. Zhou R.H., Shi Q., Gao H.Q., Shen B.J. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb 2001, 8:30-32.
31. Cunha F.Q., Lorenzetti B.B., Poole S., Ferreira S.H. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 1991, 104:765-767.
32. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998, 105:83-107.
33. Rausch S.M., Clark M.M., Patten C., Liu H., Felten S., Li Y., et al. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer 2010, 116(Suppl. 7):4103-4113.
34. Chouchane L., Ahmed S.B., Baccouche S., Remadi S. Polymorphism in the tumor necrosis factor-α promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997, 80(Suppl. 8):1489-1496.
35. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007, 137(Suppl. 1):194S-199S.
36. Rothman N., Skibola C.F., Wang S.S., Morgan G., Lan Q., Smith M.T., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006, 7(Suppl. 1):27-38.
37. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., Dahiya R. Polymorphisms of estrogen receptor [alpha] gene in endometrial cancer. Biochem Biophys Res Commun 2002, 297(Suppl. 3):558-564.
38. Shi Q., Zhang Z., Li G., Pillow P.C., Hernandez L.M., Spitz M.R. Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev 2005, 14(Suppl. 6):1477-1484.
39. Lech-Maranda E., Baseggio L., Bienvenu J., Charlot C., Berger F., Rigal D. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004, 103(Suppl. 9):3529-3534.
40. Lee J.M., Wu M.T., Lee Y.C., Yang S.Y., Chen J.S., Hsu H.H., et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 2005, 11(Suppl. 13):4749-4753.
41. Vuoristo M.S. The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma. Cancer Genet Cytogenet 2007, 176(Suppl. 1):54-57.
42. Jatoi A., Nguyen P.L., Foster N., Sun D., Stella P.J., Campbell M., et al. Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. J Support Oncol 2007, 5(Suppl. 1):41-46.
43. Zhang D., Zhou Y., Wu L., Wang S., Zheng H., Yu B., et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann Clin Lab Sci 2008, 38(Suppl. 2):113-119.
44. Andreassen C.N., Overgaard J., Alsner J., Overgaard M., Herskind C., Cesaretti J.A., et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006, 64(Suppl. 3):776-783.
45. De Ruyck K., Van Eijkeren M., Claes K., Mothier R., De Paepe A., Vral A., et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Intl J Radiat Oncol Biol Phys 2005, 62(Suppl. 4):1140-1149.
46. Quarmby S., Fakhoury H., Levine E., Barber J., Wylie J., Hajeer A.H., et al. Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 2003, 79(Suppl. 2):137-143.
47. Hussain T., Gupta S., Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003, 191(Suppl. 2):125-135.
48. Mantyh P.W., Clohisy D.R., Koltzenburg M., Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2(Suppl. 3):201-209.
49. Reyes-Gibby C.C., Spitz M.R., Yennurajalingam S., Swartz M., Gu J., Wu X., et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev 2009, 18(Suppl. 10):2636-2642.
50. Yang H., Gu J., Lin X., Grossman H.B., Ye Y., Dinney C.P., et al. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008, 14(Suppl. 7):2236-2244.
51. Vogel U., Christensen J., Wallin H., Friis S., Nexo B.A., Tjonneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007, 617(Suppl. 1-2):138-146.
52. Kim J.G., Chae Y.S., Sohn S.K., Moon J.H., Ryoo H.M., Bae S.H., et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 2009, 64(Suppl. 5):953-960.
53. Srivastava K., Srivastava A., Pandey S.N., Kumar A., Mittal B. Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population. J Gastroenterol 2009, 44(Suppl. 7):774-780.
54. Lurie G., Terry K.L., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010, 21(Suppl. 10):1731-1741.
55. Vogel U., Segel S., Dethlefsen C., Tjonneland A., Saber A.T., Wallin H., et al. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010, 209(Suppl. 1):155-162.
56. Ozhan G., Yanar T.H., Ertekin C., Alpertunga B. The effect of genetic polymorphisms of cyclooxygenase 2 on acute pancreatitis in Turkey. Pancreas 2010, 39(Suppl. 3):371-376.
57. Yu K.D., Chen A.X., Yang C., Qiu L.X., Fan L., Xu W.H., et al. Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 122(Suppl. 1):251-257.
58. Barry E.L., Sansbury L.B., Grau M.V., Ali I.U., Tsang S., Munroe D.J., et al. Cyclooxygenase-2 Polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2009, 18(Suppl. 10):2726.
59. Cuff C.A., Sacca R., Ruddle N.H. Differential induction of adhesion molecule and chemokine expression by LT α3 and LTαβ in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. J Immunol 1999, 162(Suppl. 10):5965-5972.
60. Hjelmstrom P., Fjell J., Nakagawa T., Sacca R., Cuff C.A., Ruddle N.H. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 2000, 156(Suppl. 4):1133-1138.
61. Sacca R., Cuff C.A., Lesslauer W., Ruddle N.H. Differential activities of secreted lymphotoxin-α3 and membrane lymphotoxin-α1β2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J Immunol 1998, 160(Suppl. 1):485-491.
62. Constantin C.E., Mair N., Sailer C.A., Andratsch M., Xu Z.Z., Blumer M.J., et al. Endogenous tumor necrosis factor α (TNFα) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28(Suppl. 19):5072-5081.
63. Wajant H. The role of TNF in cancer. Death Rec Cognate Ligands Cancer 2009, 49:1-15.
64. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., Maier S.F. Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia. Brain Res 1995, 692(Suppl. 1-2):244-250.
65. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128(Suppl. 1):452-462.
66. Svobodník A., Yang P., Novotny P.J., Bass E., Garces Y.I., Jett J.R., et al. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clinic Proc 2004, 79(Suppl. 8):1024-1030.
67. Ware J.E., Kosinski M. SF-36 physical & mental health summary scales: a manual for users of version 1 2001, Quality Metric Inc.
68. Colgrove L.A.A., Kim Y., Thompson N. The effect of spirituality and gender on the quality of life of spousal caregivers of cancer survivors. Ann Behav Med 2007, 33(Suppl. 1):90-98.
69. Land S.R., Wickerham D.L., Costantino J.P., Ritter M.W., Vogel V.G., Lee M., et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(Suppl. 23):E1-E10.
70. Mosconi P., Cifani S., Crispino S., Fossati R., Apolone G. The performance of SF-36 health survey in patients with laryngeal cancer. Head Neck 2000, 22(Suppl. 2):175-182.
71. Petersen L.R., Clark M.M., Novotny P., Kung S., Sloan J.A., Patten C.A., et al. Relationship of optimism-pessimism and health-related quality of life in breast cancer survivors. J Psychosoc Oncol 2008, 26(4):15-32.
72. Belsey D.A., Kuh E., Welsch R.E. Regression diagnostics: identifying influential data and sources of collinearity 1980, John Wiley & Sons, New York.
73. Sarna L., Evangelista L., Tashkin D., Padilla G., Holmes C., Brecht M.L., et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 2004 Feb, 125(2):439-445.
74. Fortner B.V., Okon T.A., Portenoy R.K. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002, 3(Suppl. 1):38-44.
75. Hwang S.S., Chang V.T., Kasimis B. Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. J Pain Symptom Manage 2002, 23(Suppl. 3):190-200.
76. Anie K.A., Steptoe A., Bevan D.H. Sickle cell disease: pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol 2002, 7(Suppl. 3):331-344.
77. Prucha E. Health reference series: cancer sourcebook 2000, Omnigraphics, Detroit (MI), p. 151-61. 3rd ed.
78. Wong W.S., Fielding R. Quality of life and pain in Chinese lung cancer patients: is optimism a moderator or mediator?. Qual Life Res 2007, 16(Suppl. 1):53-63.